Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society

Pancreas

Volumn 41, Issue 7, 2012, Pages 985-992

  Egawa, Shinichi ^a,b   Toma, Hiroki ^a,c   Ohigashi, Hiroaki ^a,d   Okusaka, Takuji ^a,e   Nakao, Akimasa ^a,f   Hatori, Takashi ^a,g   Maguchi, Hiroyuki ^h   Yanagisawa, Akio ^a,i   Tanaka, Masao ^a,c  

^a Committee for Pancreatic Cancer Registry of Japan Pancreas Society ^*  (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f NAGOYA CENTRAL HOSPITAL   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h TEINE KEIJINKAI HOSPITAL   (Japan)

ⁱ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

adjuvant therapy; classification; early diagnosis; nationwide registry; pancreatic cancer; surgical treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER REGISTRY; CANCER STAGING; HUMAN; JAPAN; LYMPH NODE DISSECTION; MEDICAL RECORD; MEDICAL SOCIETY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

ANNIVERSARIES AND SPECIAL EVENTS; CONFIDENTIALITY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; JAPAN; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; REGISTRIES; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84865863438     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318258055c     Document Type: Review

References (36)

1. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28(3):219-230.
2. Egawa S, Takeda K, Fukuyama S, et al. Clinicopathological aspects of small pancreatic cancer. Pancreas. 2004;28(3):235-240.
3. TNM History, Evolution and Milestones. Available at: http://www. uicc.org/node/7735. Accessed May 7, 2012.
4. International Union Against Cancer (UICC). In: Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours. 7th ed. New York, NY: Wiley-Liss; 2010.
5. American Joint Committee on Cancer (AJCC). In: Edge SB, Byrd DR, Compton CC, et al, eds. Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
6. Japanese Gastric Cancer Association. Japanese classification of gastric carcinomaV2nd English edition. Gastric Cancer. 1998;1:10-24.
7. Japan Pancreas Society. Classification of Pancreatic Carcinoma. 1st English Ed. Tokyo, Japan: Kanehara; 1996.
8. Japan Pancreas Society. Classification of pancreatic cancer. Second English Edition. Tokyo, Japan: Kanehara; 2003.
9. Kuroda Y, Okumura S, Saitoh Y. A manual for the staging of pancreatic cancers and the cancer registry in Japan. Nihon Rinsho. 1986;44(8):1715-1720 [in Japanese].
10. Tsuchiya R, Tsunoda T. Tumor size as a predictive factor. Int J Pancreatol. 1990;7(1-3):117-123.
11. Tsuchiya R, Tsunoda T, Ishida T, et al. Resection for cancer of the pancreasVthe Japanese experience. Baillieres Clin Gastroenterol. 1990;4(4):931-939.
12. Satake K, Takeuchi T, Homma T, et al. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas. 1994;9(6):703-706.
13. Ohashi O, Yamamoto M, Ishida H, et al. Surgical treatment of pancreatic cancer and its prognosis-long-term therapeutic results after resection. Gan To Kagaku Ryoho (in Japanese). 1996;23(12):1629-1634.
14. Yamamoto M, Ohashi O, Saitoh Y. Japan Pancreatic Cancer registry: current status. Pancreas. 1998;16(3):238-242.
15. Matsuno S, Egawa S, Shibuya K, et al. Pancreatic cancer: current status of treatment and survival of 16071 patients diagnosed from 1981-1996, using Japanese National Pancreatic Cancer Database. Int J Clin Oncol. 2000;5:153-157.
16. Matsuno S, Egawa S, Arai K. Trends in treatment for pancreatic cancer. J Hepatobiliary Pancreat Surg. 2001;8:544-548.
17. Tanaka M, Matsuno S, Isaji S, et al. Pancreatic cancer registry report 2007. Suizo. 2007;22(1):e1Ye427. with English subtitles (http://www.jstage.jst. go.jp/browse/suizo/22/1/).
18. Hirata K, Egawa S, Kimura Y, et al. Current status of surgery for pancreatic cancer. Dig Surg. 2007; 24(2): 137-147.
19. Egawa S, Sunamura M, Abe H, et al. Clinicopathological aspects of pancreatic cancer. Gan To Kagaku Ryoho. 2005;32(5):605-611 [in Japanese].
20. Matsuno S, Egawa S, Unno M. R0 resection for ductal pancreatic cancerVJapanese experience. Am J Surg. 2007;194:S110YS114.
21. Kitagami H, Kondo S, Hirano S, et al. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas. 2007;35(1):42-46.
22. Egawa S, Sunamura M, Matsuno S, et al. Surgical treatment of rare endocrine tumors. In: Beger HG, Matsuno S, Cameron JL, eds. Disease of the Pancreas. Heidelberg, Germany: Springer; 2008:735-747.
23. Fukuyama S, Matsuno S, Egawa S, et al. Outcome after surgical treatment of endocrine pancreatic tumors. In: Beger HG, Matsuno S, Cameron JL, eds. Disease of the Pancreas. Heidelberg, Germany: Springer; 2008:749-752.
24. Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40(4): 571-580.
25. Egawa S, Toma H, Ohigashi H, et al. Classification of pancreatic cancer: validation using nation-wide registry of Japan Pancreas Society. In: Watanabe HS, ed. Horizons in Cancer Research. Vol. 46. New York, NY: Nova Science Publishers. In pres.s.
26. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
27. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977-987.
28. Tanaka M, Chari S, Adsay V, et al; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
29. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007; 11(3):229-243.
30. Ji B, Tsou L, Wang H, et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 2009;137(3):1072-1082.
31. Neoptolemos JP, Dunn JA, Stocken DD, et al; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576- 1585.
32. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.
33. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908-915.
34. Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966.
35. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-1825.
36. Yamaguchi K, Tanaka M; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of Japan Pancreas Society. EBM-based clinical guidelines for pancreatic cancer 2009 from the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol. 2011;41(7):836-840.